Advanced Medical Solutions (AIM: AMS) backs £659m H.B. Fuller takeover at 285p

Advanced Medical Solutions Group plc (AIM: AMS) has agreed to a recommended cash acquisition by H.B. Fuller Company (NYSE: FUL) valuing its fully diluted equity at approximately £659 million and implying an enterprise value of £715 million. Shareholders will receive 285 pence for each Advanced Medical Solutions Group share, representing a 34.8% premium to the company’s undisturbed May 20 closing price of 212 pence. H.B. Fuller Company expects the transaction to increase its medical adhesives business more than fourfold and generate approximately US$55 million of annual revenue and cost synergies. AMS shares closed near 278 pence on June 25, leaving only a modest discount to the offer as investors assessed completion risk and whether the board had surrendered too much of the future value created by its surgical expansion.

Why did Advanced Medical Solutions Group recommend the 285 pence cash offer now?

Advanced Medical Solutions Group is not being acquired because its business is distressed. The company entered the takeover process after reporting record 2025 revenue, continued surgical growth and progress integrating Peters Surgical SAS and Syntacoll GmbH. Its directors have instead chosen to exchange the execution risk attached to that strategy for a defined cash return.

The offer provides a meaningful premium to the levels at which AMS traded before H.B. Fuller Company’s interest became public. It is also 24.5% above the highest closing price achieved during the 12 months preceding the offer period and 38.7% above the three-month undisturbed volume-weighted average price.

That comparison supports the board’s decision, particularly because the share price had failed to reflect the scale of the company’s operational transformation. Advanced Medical Solutions Group increased wider group revenue by 84% between the beginning of 2023 and the start of 2026, helped by organic expansion and the Peters Surgical acquisition. The shares nevertheless fell approximately 12% between January 2023 and the undisturbed date.

The directors therefore faced a familiar London small-cap dilemma. They could continue investing in United States commercialisation, product launches and acquisition integration without any guarantee that public investors would reward the results, or accept a cash price above the company’s historical trading range.

The offer does not prove that 285 pence represents the maximum long-term value of Advanced Medical Solutions Group. It demonstrates that the board believes the certainty of the payment, combined with the premium and remaining execution risks, outweighs the potential benefit of waiting for a higher standalone valuation.

Does the £715 million enterprise value fairly price Advanced Medical Solutions Group?

H.B. Fuller Company’s offer values Advanced Medical Solutions Group at approximately 12.9 times forecast 2026 adjusted EBITDA before synergies. The multiple falls below eight times if the buyer delivers the full annual synergy programme identified in the transaction plan.

Advanced Medical Solutions Group expects approximately £245.3 million of revenue and £55.1 million to £55.2 million of adjusted EBITDA for 2026. The acquisition therefore assigns a substantial valuation to the existing business, but it does not require H.B. Fuller Company to pay Advanced Medical Solutions Group shareholders for all the value that could emerge through integration.

This is the central tension in the deal. Shareholders receive a 34.8% premium to the undisturbed price, while H.B. Fuller Company expects approximately £41 million of annual revenue and cost benefits by 2031. Those synergies equal a large proportion of Advanced Medical Solutions Group’s standalone forecast EBITDA.

Some of the value could not realistically be achieved by Advanced Medical Solutions Group alone. The company does not possess H.B. Fuller Company’s global raw-material purchasing scale, United States original equipment manufacturer relationships or broader manufacturing platform. Other benefits, including public-company cost elimination and overlapping administrative savings, become available only after the acquisition.

However, the transaction also transfers Advanced Medical Solutions Group’s existing growth potential to the buyer. Its direct sales expansion, product launches, regulatory expertise and integration of Peters Surgical were already progressing before the takeover.

The offer consequently appears fair rather than extravagant. It compensates investors for surrendering the independent company, while leaving H.B. Fuller Company with enough potential value to justify the price, financing costs and integration risk.

Why does H.B. Fuller Company want a surgical adhesives platform rather than another small bolt-on?

H.B. Fuller Company has built its healthcare position through a series of acquisitions, including Tissue Seal, Adhezion Biomedical, Medifill and GEM. Advanced Medical Solutions Group is materially larger and broader than those earlier transactions, making the acquisition a platform deal rather than another incremental addition.

The combined medical adhesive technologies operation is expected to generate approximately US$370 million of pro forma revenue, compared with about US$68 million for H.B. Fuller Company’s existing medical adhesives activities. Advanced Medical Solutions Group would therefore account for most of the enlarged division from the outset.

Advanced Medical Solutions Group brings surgical tissue adhesives, internal fixation devices, biosurgical sealants, haemostatic and antibiotic collagen products, mechanical closures and advanced wound dressings. Its brands include LiquiBand, LIQUIFIX, RESORBA, Seal-G, Syntacoll and ActivHeal.

The portfolio gives H.B. Fuller Company a broader route into surgical procedures rather than limiting it to adhesives used by medical device manufacturers. It also creates access to hospitals, clinicians, specialist distributors and healthcare systems across Europe and other international markets.

Advanced Medical Solutions Group’s more than 75 research and development employees and regulatory capabilities provide another strategic asset. Medical device products require testing, clinical evidence, quality systems and approvals that can take years to establish. Acquiring an experienced development and regulatory platform may reduce the time and risk involved in expanding organically.

The buyer is essentially purchasing products, clinical credibility, distribution and regulatory infrastructure together. That combination is harder to reproduce than a single adhesive formulation and explains why Advanced Medical Solutions Group commands a higher strategic value than a typical industrial adhesives acquisition.

Can the US$55 million synergy target be delivered without weakening innovation?

H.B. Fuller Company expects approximately US$20 million of commercial synergies and US$35 million of cost synergies. More than half of the combined benefits are expected by 2028, with full cost savings targeted by 2030 and the total programme by 2031.

The commercial opportunity centres on cross-selling. H.B. Fuller Company can distribute Advanced Medical Solutions Group products through its United States infrastructure, while its own medical technologies can gain access to Advanced Medical Solutions Group’s European sales teams and distributor network.

This could accelerate the United States expansion of products such as LiquiBand, LIQUIFIX and the wider Peters Surgical portfolio. The buyer may also capture distributor margins by moving selected products through direct sales channels where scale supports that approach.

Cost savings are expected from public-company cost removal, overlapping administrative activities, sourcing efficiencies and manufacturing integration. H.B. Fuller Company also plans to apply its procurement capabilities to Advanced Medical Solutions Group’s raw-material and indirect expenditure.

Those savings carry execution risk. Medical adhesives, woundcare products and surgical devices operate within tightly controlled quality and regulatory systems. Changing suppliers, materials, processes or production locations can require validation and regulatory work before financial savings are realised.

Aggressive cost reduction could also weaken product development. Advanced Medical Solutions Group’s attractiveness partly rests on its research capabilities and record of launching clinically relevant products. Reducing technical or regulatory resources to achieve a short-term margin target would damage the strategic asset H.B. Fuller Company is paying to acquire.

H.B. Fuller Company has said it does not intend to reduce Advanced Medical Solutions Group’s existing research and development functions. The credibility of the synergy case will depend on maintaining that commitment while pursuing savings in administrative, procurement and manufacturing areas.

How does the Peters Surgical acquisition strengthen the case for the H.B. Fuller deal?

Advanced Medical Solutions Group completed the acquisition of Peters Surgical in 2024, expanding into sutures, mechanical closures, vascular clips and other surgical products. Peters Surgical contributed approximately £74 million of revenue during 2025 and helped increase total group revenue to £228.9 million.

The acquisition broadened Advanced Medical Solutions Group’s hospital relationships and geographic reach, particularly in Europe, India and other international markets. It also provided opportunities to sell legacy Advanced Medical Solutions Group products through the acquired organisation.

Peters Surgical remains in the integration phase. Advanced Medical Solutions Group has been consolidating sutures operations from six sites to two and collagen manufacturing from two locations to one. The restructuring is expected to reduce headcount in Germany and the Czech Republic and produce additional operational benefits from 2027.

H.B. Fuller Company inherits both the potential upside and the unfinished work. It can combine Peters Surgical manufacturing with its own medical operations, integrate procurement and use the wider portfolio to deepen relationships with hospitals and distributors.

The timing may be attractive for the buyer because some integration costs have already been incurred while a larger share of the benefits remains ahead. H.B. Fuller Company is acquiring Advanced Medical Solutions Group after the strategic expansion but before the full margin contribution has become visible.

For departing shareholders, this creates a legitimate concern that the business is being sold shortly before Peters Surgical begins contributing more meaningfully to profitability. The counterargument is that integration risk remains real and shareholders are receiving cash rather than waiting for the manufacturing consolidation and commercial synergies to arrive.

Will acquisition debt and higher leverage constrain H.B. Fuller Company after completion?

H.B. Fuller Company will finance the cash consideration through a fully committed unsecured bridge facility. The structure provides transaction certainty, but it will increase leverage at a time when the buyer is already managing a sizeable debt position.

Net leverage is expected to reach approximately four times pro forma adjusted EBITDA immediately after completion, or 3.7 times when full run-rate synergies are included. H.B. Fuller Company intends to reduce that figure to its target range of 2.5 to three times within two years.

That deleveraging plan depends on cash generation, synergy delivery and disciplined capital allocation. It may limit the company’s capacity for further large acquisitions, share repurchases or rapid discretionary investment during the initial integration period.

H.B. Fuller Company reported second-quarter 2026 revenue of approximately US$950.3 million and adjusted EBITDA of US$181 million, while raising its full-year outlook. The operating performance gives it a stronger base from which to absorb the acquisition.

The market response was less enthusiastic. FUL shares traded near US$59.84 on June 25, down about 7% during the session and within a 52-week range of approximately US$48.71 to US$68.63. The movement reflected the combined effect of the acquisition announcement and the latest earnings release, but it signals concern about the price, leverage or complexity of the transaction.

The acquisition can create value if Advanced Medical Solutions Group raises H.B. Fuller Company’s growth rate and margin as projected. Failure to capture synergies would leave the buyer with higher debt and a business acquired at a considerably less attractive multiple.

What does the AMS share-price reaction reveal about takeover completion expectations?

AMS shares closed near 278 pence on June 25 after reaching a new 52-week high of 279.5 pence. The closing level was approximately 2.5% below the 285 pence cash offer.

The shares increased about 15.8% during the session, around 21.9% from their June 18 close of 228 pence and approximately 24.9% from the May 22 close of 222.5 pence. The 52-week range now stands at roughly 187 pence to 279.5 pence.

The relatively narrow discount to the offer indicates that investors consider completion highly probable. The transaction has unanimous support from both boards, committed financing and an agreed scheme structure.

The remaining spread compensates investors for the time required to obtain approvals and the possibility that a condition is not satisfied. Completion is expected by the end of 2026, meaning shareholders may wait several months for the cash consideration.

Investors on the register for the final dividend will also receive 2.01 pence per share on June 26. H.B. Fuller Company has specifically excluded that dividend from the distributions that could reduce the takeover consideration, although investors buying after the ex-dividend date will not receive it.

There is limited evidence that the market expects a competing bidder. The shares remain below 285 pence rather than trading at or above the offer price, which would normally indicate speculation about an improved proposal.

A rival cannot be ruled out because Advanced Medical Solutions Group owns attractive regulated assets and the medical adhesives market remains fragmented. However, H.B. Fuller Company has completed negotiations, secured a board recommendation and articulated substantial buyer-specific synergies, creating a higher hurdle for another bidder.

Could regulatory approvals delay the Advanced Medical Solutions Group takeover?

The acquisition requires approval from Advanced Medical Solutions Group shareholders and sanction by the High Court of Justice in England and Wales. The scheme must receive support from a majority in number of voting shareholders representing at least 75% of the shares voted.

Merger control conditions may apply in Austria, Germany, the United Kingdom and the United States. Foreign investment approvals may also be required in Austria, France and Luxembourg.

The number of jurisdictions reflects the global manufacturing, sales and research footprint of the two companies. It does not necessarily indicate that regulators will identify major competition concerns.

H.B. Fuller Company and Advanced Medical Solutions Group overlap in medical adhesives, but the sector remains fragmented and includes numerous multinational and specialist competitors. The buyer has stated that no single company holds more than 20% in most medical subsegments.

The combination is therefore more likely to be viewed as a significant expansion than the creation of an overwhelmingly dominant supplier. Regulators may still examine particular product categories, geographic markets or customer relationships where the companies compete directly.

Foreign investment reviews will focus on ownership, technology, manufacturing and healthcare supply considerations. H.B. Fuller Company is an established United States industrial group rather than an unfamiliar financial buyer, which may reduce some political concerns.

The scheme document is expected within 28 days and will provide the detailed meeting and transaction timetable. The acquisition is currently targeted to complete by December 31, 2026, subject to the approvals and court process.

What could the transaction mean for employees, manufacturing sites and research teams?

Advanced Medical Solutions Group employs more than 1,800 people across 22 locations, including 17 manufacturing sites and 11 research and development facilities. H.B. Fuller Company employs approximately 7,100 people globally.

The buyer expects some duplication in corporate and administrative functions. Listed-company roles will no longer be required after Advanced Medical Solutions Group leaves AIM, while overlapping back-office positions in the United States, United Kingdom and European Union may be reviewed.

H.B. Fuller Company does not currently expect these takeover-related reductions to be material compared with Advanced Medical Solutions Group’s overall headcount. They will, however, come in addition to the manufacturing consolidation already planned in Germany and the Czech Republic.

The existing Advanced Medical Solutions Group headquarters in Winsford is expected to remain a key operating hub for the enlarged medical adhesive technologies division. H.B. Fuller Company has not identified plans for significant additional site closures or redeployment of major fixed assets.

Maintaining specialist employees will be essential. Regulatory, quality, clinical and manufacturing expertise represents a substantial part of Advanced Medical Solutions Group’s value and cannot be replaced quickly after aggressive restructuring.

The takeover is therefore unlikely to follow a simple cost-cutting template. H.B. Fuller Company needs enough administrative savings to support its synergy target, but it also needs the scientific, manufacturing and commercial capabilities that justified paying £715 million.

Does the takeover highlight another London valuation gap for growing healthcare companies?

Advanced Medical Solutions Group delivered a total shareholder return of approximately 245% between January 2011 and the start of the offer period. Its more recent share-price performance was less impressive, despite substantial growth in revenue and strategic capability.

The company considered moving from AIM to the Main Market as one possible route to improved valuation. The board ultimately concluded that a different listing would not guarantee that investors would recognise the company’s growth potential.

H.B. Fuller Company can pay a large premium and still describe the acquisition as financially attractive because of the gap between Advanced Medical Solutions Group’s public valuation and its strategic value inside a larger global group.

This is another example of international buyers acquiring established British companies after the public market has been slow to price operational progress. Shareholders receive an immediate gain, but future value from United States expansion, Peters Surgical integration and procurement savings transfers to the buyer.

The transaction is not necessarily evidence that the board failed. Directors must consider certainty, liquidity, market conditions and execution risk rather than assume every independent strategy will eventually receive a fair valuation.

It does, however, reinforce a difficult question for London. When profitable healthcare technology businesses can be purchased at substantial premiums while remaining accretive to overseas buyers, the public market may be pricing the companies rather than the assets.

Which milestones will decide whether AMS shareholders receive the 285 pence cash payment?

The first milestone will be publication of the scheme document, expected within 28 days of the June 25 announcement. It will contain the shareholder meeting dates, regulatory timetable and detailed conditions.

Shareholders must then approve the transaction at the court meeting and general meeting. Directors holding approximately 0.34% of the existing share capital have given irrevocable commitments to support the acquisition.

Competition and foreign investment approvals will follow across the relevant jurisdictions. Any extended review could push completion towards the end of the announced timetable.

The High Court must sanction the scheme after shareholder and regulatory conditions are satisfied. The court order must then be delivered to the Registrar of Companies before the acquisition becomes effective.

Trading in AMS shares will be cancelled shortly after completion, and Advanced Medical Solutions Group will be re-registered as a private company within H.B. Fuller Company.

The market currently expects that sequence to succeed. The modest deal spread offers limited additional upside compared with the risk of a material decline if the transaction fails, meaning new investors are effectively making a completion-probability judgment rather than buying the standalone growth story.

Key takeaways on the H.B. Fuller offer, AMS valuation and takeover outlook

• H.B. Fuller Company has agreed to acquire Advanced Medical Solutions Group for 285 pence per share in cash.
• The offer values the fully diluted equity at approximately £659 million and implies a £715 million enterprise value.
• The consideration represents a 34.8% premium to the undisturbed May 20 closing price of 212 pence.
• Advanced Medical Solutions Group expects approximately £245.3 million of 2026 revenue and £55.1 million to £55.2 million of adjusted EBITDA.
• The transaction values the company at 12.9 times forecast EBITDA before synergies and below eight times after full synergies.
• H.B. Fuller Company expects approximately US$55 million of annual revenue and cost benefits by 2031.
• The acquisition will increase H.B. Fuller Company’s medical adhesives revenue from approximately US$68 million to around US$370 million.
• AMS shares closed near 278 pence, around 2.5% below the cash offer and close to their new 52-week high.
• H.B. Fuller Company expects leverage to rise to approximately four times adjusted EBITDA before falling towards 2.5 to three times within two years.
• Shareholder, court, competition and foreign investment approvals remain necessary before the expected year-end completion.